Next Article in Journal
Efforts at COVID-19 Vaccine Development: Challenges and Successes
Previous Article in Journal
DNA Vaccine Development at Pre- and Post-Operation Warp Speed

Meningococcal Vaccines: Challenges and Prospects

Center for Drug Delivery Research, Vaccine Nanotechnology Laboratory, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA
Fraunhofer USA Center for Molecular Biotechnology, Newark, DE 19711, USA
College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Vaccines 2020, 8(4), 738;
Received: 5 November 2020 / Accepted: 5 November 2020 / Published: 4 December 2020
Note: In lieu of an abstract, this is an excerpt from the first page.

Neisseria meningitidis is a gram-negative bacterium that causes a severe acute infection, called the meningococcal disease [...] View Full-Text
MDPI and ACS Style

Bagwe, P.; Bajaj, L.; Gala, R.; Zughaier, S.M.; Uddin, M.N.; D’Souza, M.J. Meningococcal Vaccines: Challenges and Prospects. Vaccines 2020, 8, 738.

AMA Style

Bagwe P, Bajaj L, Gala R, Zughaier SM, Uddin MN, D’Souza MJ. Meningococcal Vaccines: Challenges and Prospects. Vaccines. 2020; 8(4):738.

Chicago/Turabian Style

Bagwe, Priyal, Lotika Bajaj, Rikhav Gala, Susu M. Zughaier, Mohammad N. Uddin, and Martin J. D’Souza 2020. "Meningococcal Vaccines: Challenges and Prospects" Vaccines 8, no. 4: 738.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop